Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis
Two Therapies That Could Rival Dupixent
As the European Academy of Dermatology and Venerology congress closed its doors, two OX40 atopic dermatitis drugs from Sanofi and Amgen/Kyowa Kirin caught the eye.
